Dermata Therapeutics, Inc. financial data

Symbol
DRMA, DRMAW on Nasdaq
Industry
Pharmaceutical Preparations
Location
3525 Del Mar Heights Rd., #322, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 37.7 % +188%
Return On Equity -247 % -141%
Return On Assets -180 % -97.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.04M shares -36%
Common Stock, Shares, Outstanding 1.68M shares -47.4%
Entity Public Float 4.8M USD +20%
Common Stock, Value, Issued 168 USD -47.3%
Weighted Average Number of Shares Outstanding, Basic 8.35M shares +337%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 7.15M USD +86.9%
General and Administrative Expense 4.39M USD +18.2%
Operating Income (Loss) -11.5M USD -53.1%
Net Income (Loss) Attributable to Parent -11.3M USD -53.8%
Earnings Per Share, Basic -2.67 USD/shares +80.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.63M USD -17.8%
Assets 6.69M USD -8.69%
Accounts Payable, Current 864K USD +82%
Liabilities 1.95M USD +112%
Retained Earnings (Accumulated Deficit) -62.5M USD -22%
Stockholders' Equity Attributable to Parent 4.74M USD -26%
Liabilities and Equity 6.69M USD -8.69%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.7M USD -63.9%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 1.68M shares -47.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.14M USD -7.36%
Deferred Tax Assets, Valuation Allowance 5.46M USD +47.3%
Deferred Tax Assets, Gross 5.46M USD +47.3%
Deferred Tax Assets, Operating Loss Carryforwards 2.98M USD +54.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 645K USD +15.8%
Additional Paid in Capital 67.3M USD +16.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 235K USD +64.7%
Interest Expense 655 USD -100%